Hyperuricemia and cardiovascular risk

High Blood Pressure and Cardiovascular Prevention

Volumn 21, Issue 4, 2014, Pages 235-242

  Grassi, Davide ^a   Desideri, Giovambattista ^a   Di Giacomantonio, Anna Vittoria ^a   Di Giosia, Paolo ^a   Ferri, Claudio ^a  

^a UNIVERSITY OF L'AQUILA   (Italy)

Author keywords

Cardiovascular risk; Hypertension; Metabolic risk; Uric acid

Indexed keywords

URIC ACID;

ARTICLE; CARDIOMETABOLIC RISK; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COMORBIDITY; HUMAN; HYPERURICEMIA; CARDIOVASCULAR DISEASES; COMPLICATION; EVIDENCE BASED MEDICINE; GOUT; RISK FACTOR;

CARDIOVASCULAR DISEASES; EVIDENCE-BASED MEDICINE; GOUT; HUMANS; HYPERURICEMIA; RISK FACTORS;

EID: 84916597128     PISSN: 11209879     EISSN: 11791985     Source Type: Journal    
DOI: 10.1007/s40292-014-0046-3     Document Type: Article

References (37)

1. Richette P, Bardin T. Gout. Lancet 2010; 375 (9711):318–328.
2. Choi HK, Mount DB, Reginato AM. Pathogenesis of gout. Ann Intern Med. 2005;143:499–516.
3. Johnson RJ, Rideout BA. Uric acid and diet-insights into the epidemic of cardiovascular disease. N Engl J Med. 2004;350:1071–3.
4. Edwards NL. The role of hyperuricemia and gout in kidney and cardiovascular disease. Cleve Clin J Med. 2008;75(Suppl 5):S13–6.
5. Gustafsson D, Unwin R. The pathophysiology of hyperuricaemia and its possible relationship to cardiovascular disease, morbidity and mortality. BMC Nephrol. 2013;14:164.
6. Wortmann RL. Gout and hyperuricemia. Curr Opin Rheumatol. 2002;14:281–6.
7. Saag KG, Mikuls TR. Recent advances in the epidemiology of gout. Curr Rheumatol Rep. 2005;7:235–41.
8. Grassi D, Ferri L, Desideri G, Di Giosia P, Cheli P, Del Pinto R, Properzi G, Ferri C. Chronic hyperuricemia, uric acid deposit and cardiovascular risk. Curr Pharm Des. 2013;19(13):2432–8.
9. Johnson RJ, Kang DH, Feig D, Kivlighn S, Kanellis J, Watanabe S, Tuttle KR, Rodriguez-Iturbe B, Herrera-Acosta J, Mazzali M. Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease? Hypertension. 2003;41:1183–90.
10. Yoo TW, Sung KC, Shin HS, et al. Relationship between serum uric acid concentration and insulin resistance and metabolic syndrome. Circ J. 2005;69:928–33.
11. Ferri C, Ferri L, Grassi D. Uric acid as a marker and contributor to cardiovascular disease. Cardiol Clin Pract. 2011;3(1):1–11.
12. Cannon PJ, Stason WB, Demartini FE, Sommers SC, Laragh JH. Hyperuricemia in primary and renal hypertension. N Engl J Med. 1966;275:457–64.
13. Perlstein TS, Gumieniak O, Williams GH, et al. Uric acid and the development of hypertension: the normative aging study. Hypertension. 2006;48(6):1031–6.
14. Messerli FH, Frohlich ED, Dreslinski GR, Suarez DH, Aristimuno GG. Serum uric acid in essential hypertension: an indicator of renal vascular involvement. Arch Intern Med. 1980;93:817–21.
15. Friedl HP, Smith DJ, Till GO, Thomson PD, Louis DS, Ward PA. Ischemia-reperfusion in humans. Appearance of xanthine oxidase activity. Am J Pathol. 1990;136(3):491–5.
16. Ferrannini E, Galvan AQ, Gastaldelli A, Camastra S, Sironi AM, Toschi E, Baldi S, Frascerra S, Monzani F, Antonelli A, Nannipieri M, Mari A, Seghieri G, Natali A. Insulin: new roles for an ancient hormone. Eur J Clin Investig. 1999;29(10):842–52.
17. Gonçalves JP, Oliveira A, Severo M, Santos AC, Lopes C. Cross-sectional and longitudinal associations between serum uric acid and metabolic syndrome. Endocrine. 2012;41(3):450–7.
18. Rodrigues SL, Baldo MP, Capingana P, Magalhães P, Dantas EM, Molina Mdel C, Salaroli LB, Morelato RL, Mill JG. Gender distribution of serum uric acid and cardiovascular risk factors: population based study. Arq Bras Cardiol. 2012;98(1):13–21.
19. Fam AG. Gout, diet, and the insulin resistance syndrome. J Rheumatol. 2002;29:1350–5.
20. Facchini F, Chen YD, Hollenbeck CB, Reaven GM. Relationship between resistance to insulin-mediated glucose uptake, urinary uric acid clearance, and plasma uric acid concentration. JAMA. 1991;266(21):3008–11.
21. Dessein PH, Shipton EA, Stanwix AE, Joffe BI, Ramokgadi J. Beneficial effects of weight loss associated with moderate calorie/ carbohydrate restriction, and increased proportional intake of protein and unsaturated fat on serum urate and lipoprotein levels in gout: a pilot study. Ann Rheum Dis. 2000;59:539–43.
22. Cicero AF, Salvi P, D’Addato S, Rosticci M, Borghi C, Brisighella Heart Study group. Association between serum uric acid, hypertension, vascular stiffness and subclinical atherosclerosis: data from the Brisighella Heart Study. J Hypertens. 2014;32(1):57–64.
23. Liese AD, Hense HW, Lowel H, et al. Association of serum acid with all-cause and cardiovascular disease and incident myocardial infarction in the MONICA Augsburg cohort. World Health Organization monitoring trends and determinants in cardiovascular diseases. Epidemiology. 1999;10:391–7.
24. Hoieggen A, et al. The impact of serum uric acid on cardiovascular outcomes in the LIFE study. Kidney Int. 2004;65:1041–9.
25. Bos MJ, Koudstaal PJ, Hofman A, Witteman JCM, Breteker MMB. Uric acid is a risk factor for myocardial infarction and stroke. Stroke. 2006;37:1503–7.
26. Krishnan E, Baker JF, Furst DE, Schumacher HR. Gout and the risk of acute myocardial infarction. Arthritis Rheum. 2006;54:2688–96.
27. Brand FN, McGee DL, Kannel WB, Stokes J III, Castelli WP. Hyperuricemia as a risk factor of coronary heart disease: the Framingham Study. Am J Epidemiol. 1985;121:11–8.
28. Culleton BF, Larson MG, Kannel WB, Levy D. Serum uric acid and risk for cardiovascular disease and death: the Framingham Heart Study. Ann Intern Med. 1999;131:7–13.
29. Strasak A, Ruttmann E, Brant L, et al. Serum uric acid and risk of cardiovascular mortality: a prospective long-term study of 83683 Austrian men. Clin Chem. 2008;54:273–84.
30. Loachimescu AG, Brennan DM, Hoar BM, Hazen SL, Hoogwerf BJ. Serum uric acid is an independent predictor of all-cause mortality in patients at high risk of cardiovascular disease: a preventive cardiology information system (PreCIS) database cohort study. Arthritis Rheum. 2008;58(2):623–30.
31. Verdecchia P, Schillaci G, Reboldi G, et al. Relation between serum uric acid and risk of cardiovascular disease in essential hypertension: the PIUMA study. Hypertension. 2000;36:1072–8.
32. Kim SY, Guevara JP, Kim KM, et al. Hyperuricemia and coronary heart disease: a systematic review and meta-analysis. Arthritis Care Res (Hoboken). 2010;62(2):170–80.
33. Kim SY, Guevara JP, Kim KM, et al. Hyperuricemia and risk of stroke: a systematic review and meta-analysis. Arthritis Rheum. 2009;61(7):885–92.
34. Khosla UM, Zharikov S, Finch JL, et al. Hyperuricemia induces endothelial dysfunction. Kidney Int. 2005;67(5):1739–42.
35. Kanellis J, Kang DH. Uric acid as a mediator of endothelial dysfunction, inflammation, and vascular disease. Semin Nephrol. 2005;25(1):39–42.
36. Coronel F, Garcıa-Menal M, Herrero JA, et al. Irbesartan in hypertensive non-diabetic advanced chronic kidney disease: comparative study with ACEI. Nefrologia. 2008;28(1):56–60.
37. Becker MA, Schumacher HR, MacDonald PA, et al. Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout. J Rheumatol. 2009;36(6):1273–82.